Related Experiment Video
Updated: Mar 8, 2026
07:30
Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression
Published on: June 15, 2019
10.7K
AspiriN To Inhibit SEPSIS (ANTISEPSIS) randomised controlled trial protocol
Damon P Eisen1,2,3, Elizabeth M Moore3, Karin Leder3,4
1Townsville Hospital and Health Service, Townsville, Queensland, Australia.
BMJ Open
|January 23, 2017
Summary
Low-dose aspirin may reduce sepsis deaths and hospitalizations in older adults. The AspiriN To Inhibit SEPSIS (ANTISEPSIS) trial investigated this effect in the elderly, with results pending. Further research will clarify aspirin's role in sepsis prevention.
Area of Science:
- Gerontology and Geriatric Medicine
- Infectious Diseases and Microbiology
- Pharmacology and Pharmaceutical Sciences
Background:
- Sepsis is a significant cause of mortality and morbidity globally, particularly affecting the elderly.
- In-hospital care costs for elderly sepsis patients are substantial.
- Preliminary evidence suggests aspirin may mitigate infection-related inflammation.
Purpose of the Study:
- To determine if low-dose aspirin reduces sepsis-related mortality in older individuals.
- To assess the impact of low-dose aspirin on sepsis-related hospitalizations and ICU admissions.
- To evaluate the safety and efficacy of aspirin as an accessible therapy for sepsis in the elderly.
Main Methods:
- The AspiriN To Inhibit SEPSIS (ANTISEPSIS) trial is a substudy of the ASPirin in Reducing Events in the Elderly (ASPREE) trial.
- A double-blinded, randomized, placebo-controlled design involving 16,703 Australian participants aged 70+.
- Intervention: Daily 100mg enteric-coated aspirin versus placebo; Primary outcome: sepsis-related death.
Main Results:
- This is a pre-results abstract; therefore, no main results are available.
- The study is registered under ACTRN12613000349741.
- Data collection for the ANTISEPSIS substudy was conducted between 2012 and 2018.
Conclusions:
- The ANTISEPSIS substudy aims to provide crucial data on aspirin's potential to reduce sepsis-related adverse events in older adults.
- Positive findings could lead to significant public health benefits and reduced healthcare costs associated with sepsis in the elderly.
- The study's findings will inform clinical practice regarding aspirin use for sepsis prevention in geriatric populations.
